Journal
NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 52, Issue 3, Pages 208-215Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13139-017-0505-6
Keywords
Peptide receptor radionuclide therapy; Neuroendocrine tumors; Radiolabeled somatostatin analogues; Lu-177
Ask authors/readers for more resources
Peptide receptor radionuclide therapy (PRRT) is a systemic cytotoxic radiation therapy using a compound of beta-emitting radionuclide chelated to a peptide for the treatment of tumor with overexpressed specific cell receptor such as somatostatin receptor subtype 2 (SSTR2) of neuroendocrine tumor (NET). Surgical resection should be performed for the curative treatment for NETs when it is feasible; however, a multi-disciplinary approach is needed when locally advanced or metastasized disease. PRRT with lutetium-177 (Lu-177)-labeled somatostatin analogues, as a new treatment modality targeting metastatic or inoperable NETs expressing the SSTR2, have been developed and successfully used for the past two decades. As Lu-177 emits both beta- and gamma-radiation, it has the ability as a theragnostic agent for NETs compared with only beta-emitting yttrium-90 labeled PRRT. Several recent studies reported that Lu-177 gave an overall positive response and improved the patients' quality of life. To fully exploit its potential, large comparative studies are needed for the assessment of distinct efficacies of Lu-177 labeled PRRT. Additionally, for extending the indications and developing new regimens of Lu-177-based PRRT, more dedicated clinical research is required.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available